Customized Energy Solutions is at the forefront of competitive energy markets. Established in 1998, CES was created to assist clients in managing the changes in the wholesale and retail electric markets. As the industry restructured, many participants recognized the value of creating sound market rules and staying abreast of market changes. Thus, Customized Energy Solutions was created to address the need to simplify, analyze, and influence the markets on behalf of our clients. Our clients can focus on running their businesses, while we focus on removing barriers to them doing so. Our MISSION Customized Energy Solutions is committed to promoting economic development through the advancement of transparent, efficient, and nondiscriminatory wholesale and retail electricity and natural gas energy markets. We focus on empowering our clients by sharing our understanding of the workings of the energy markets and related new technologies and supporting our clients operations in those markets. Through all things, we desire to honor God and our clients through the quality of our services and solutions. Our VISION To have a world-wide presence wherever deregulated electricity or natural gas markets exist. To materially accelerate the commercial application of new energy technologies and free energy market structures. To represent the highest level of energy information technology and services available to clients world-wide. Our AWARDS Customized Energy Solutions Ltd. has been recognized regionally and nationally for its impressive and sustained growth, including INC. 500 | 5000 and The Philadelphia Business Journal as a Top 100 Companies in Philadelphia, Hall of Fame for five or more consecutive years. It was ranked as one of the Best Places to Work in 2013 by the Philadelphia Business Journal.

Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery, development, and delivery of DNA vaccines with a focus on cancers and infectious diseases. The company’s SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include human papillomavirus/cervical cancer (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), and hepatitis C virus and human immunodeficiency virus vaccines. It is also advancing preclinical research and clinical development for a seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.